API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.
Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology Product Name: Lidocaine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: $440.0 million Upfront Cash: $330.0 million
Deal Type: Acquisition January 31, 2020
Details:
ST-01 is a controlled release formulation of lidocaine, a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels preventing pain signals at the nerve endings. It is being developed for acute post-operative pain.
Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology Product Name: ST-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Lidocaine hydrochloride is a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.
Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology Product Name: Lidocaine Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Amneal has received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for treatment of post-herpetic neuralgia.
Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology Product Name: Lidocaine HCl- Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020